Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.32. Hemispherx BioPharma shares last traded at $0.27, with a volume of 1,527,490 shares traded.
Hemispherx BioPharma Stock Down 8.2 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than Hemispherx BioPharma
- What is the S&P/TSX Index?
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- The How and Why of Investing in Gold Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Health Care Stocks Explained: Why You Might Want to Invest
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.